Meir MC
Welcome,         Profile    Billing    Logout  
 7 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shitrit, David
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/24
12/24
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Calendar Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in Japan (based on MATINEE trial) for COPD
Active, not recruiting
3
806
Europe, Canada, Japan, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD
Pulmonary Disease, Chronic Obstructive
08/24
08/24
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Recruiting
3
576
Europe, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
06/25
06/25
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Nov 2023 - Dec 2023 : Acceptance of regulatory submission in China for chronic rhinosinusitis with nasal polyps
Recruiting
3
1700
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
09/25
09/25
NCT05483907: To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF

Hourglass Jul 2023 - Dec 2023 : Interim data for the treatment of IPF
Checkmark Initiation of trial in idiopathic pulmonary fibrosis
Nov 2022 - Nov 2022: Initiation of trial in idiopathic pulmonary fibrosis
Recruiting
2
120
Europe, US, RoW
BBT-877, Placebo
Bridge Biotherapeutics, Inc.
Idiopathic Pulmonary Fibrosis
11/24
12/24
Avital, Shmuel
ITCORA, NCT03316677: Intraoperative Testing of Colorectal Anastomosis - Air or Water (Methylene Blue)?

Not yet recruiting
N/A
150
NA
Intraoperative testing of colorectal anastomoses, Stapled colorectal anastomoses
Meir Medical Center
ColoRectal Cancer, Colonic Diverticulitis, Anastomotic Leak, Anastomotic Complication, Anastomosis
12/19
12/22
Vishlitzky, Victor
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
SURMOUNT-ADOLESCENTS-2, NCT06439277: A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities

Not yet recruiting
3
300
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Weight Gain
05/27
06/27
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
NCT04608305: Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine

Completed
1/2
843
RoW
IIBR-100, low dose (prime), IIBR-100 medium dose (prime), IIBR-100 high-dose (prime), IIBR-100 low-dose (prime-boost), Saline Placebo (single), Saline Placebo (double), IIBR-100 medium-dose (prime-boost), IIBR-100 high-dose (prime-boost), IIBR-100 top-dose (prime-boost)
Israel Institute for Biological Research (IIBR)
Covid19
10/22
10/22
Amichai, Boaz
No trials found
Amir, Linor Shushan
No trials found

Download Options